Tarsus Pharmaceuticals, Inc. (TARS)

NMS – Цена в реальном времени. Валюта: USD

62.92

-1.42 (-2.21%)

При закрытии: Jun 26, 2026, 4:00 PM EDT

62.92

0.00 (0.00%)

После закрытия: Jun 26, 2026, 5:27 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Tarsus Pharmaceuticals, Inc. (TARS)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Tarsus Pharmaceuticals, Inc. (TARS)

Tarsus to Participate in Upcoming Investor Conferences

Tarsus Q1 Review: Strong Earnings, But Wall Street Wanted A Guidance Raise

Tarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million Americans

Tarsus Pharmaceuticals, Inc. (TARS) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Tarsus to Participate in Upcoming Investor Conferences

Tarsus Pharmaceuticals, Inc. (TARS) Q1 2026 Earnings Call Transcript

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Beats Revenue Estimates

Видео

No Data

Пресс-релизы

Tarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million Americans

Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements

Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease

TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus

Search stocks

Tarsus Pharmaceuticals, Inc. (TARS)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Tarsus Pharmaceuticals, Inc. (TARS)

Tarsus to Participate in Upcoming Investor Conferences

Tarsus Q1 Review: Strong Earnings, But Wall Street Wanted A Guidance Raise

Tarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million Americans

Tarsus Pharmaceuticals, Inc. (TARS) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Tarsus to Participate in Upcoming Investor Conferences

Tarsus Pharmaceuticals, Inc. (TARS) Q1 2026 Earnings Call Transcript

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Beats Revenue Estimates

Видео

No Data

Пресс-релизы

Tarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million Americans

Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements

Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease

TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus